The Office of Public Policy (OPP) works to advance legislation to provide robust federal funding for cancer research and also supports policies aimed at enhancing clinical trials and promoting a drug development and review paradigm that is focused on what matters most to patients.
Clinical trials are the primary vehicle for developing new treatments for patients with cancer, and patient participation in trials is crucial to their success. Most patients express a willingness to participate in clinical research, yet a small fraction ultimately enroll in a cancer clinical trial. As a result, approximately 20% of cancer clinical trials fail due to insufficient patient participation. In the era of ...
The U.S. Food & Drug Administration’s (FDA) mission has always centered on promoting and protecting the public’s health. In recent years, the agency has demonstrated a commitment to accelerating patient access to innovative cancer treatments that are both safe and effective. The FDA has expanded its focus to incorporate the input of patients in the regulatory process, help promote robust competition that can help...
As an organization that has funded more than $1.2 billion in cancer research, LLS knows firsthand the importance of funding research in order to one day achieve a world without blood cancers. The federal government is the largest funder of cancer research in the world, which is why LLS supports bolstering these funding resources. To support this work, LLS advocates for robust federal investments for: The Nati...
LLS advocates sent more than 2,400 letters asking Congress to increase funding for critical cancer research at the NIH. Thanks to this outpouring of support, Congress has allocated $3 billion in new research funding, which will improve cancer patients' lives and bring us that much closer to a cure.